Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo.
Try Elite for Free
Login Sign up free
Home Screener Maps Charts News Groups Insider Futures Forex Crypto Portfolio Calendar
Pricing

New feature:   Introducing the Finviz Matrix

Learn More
Market News Market Pulse Stocks News ETF News Crypto News

Cardiff Oncology, Inc.

Contributing Author

Recent Articles by Cardiff Oncology, Inc.

Sep-14
Cardiff Oncology and Nerviano Medical Sciences Amend their 2017 Exclusive License Agreement CRDF +8.26% GlobeNewswire
Sep-02
Cardiff Oncology to Participate in September 2026 Conferences CRDF GlobeNewswire
Aug-11
Cardiff Oncology Reports Second Quarter 2026 Results and Provides Business Update CRDF CRDF -5.67% GlobeNewswire
Jul-15
Cardiff Oncology Announces $10 Million Registered Direct Offering CRDF -32.11% GlobeNewswire
Jun-02
Cardiff Oncology Announces Presentation of Positive Results from its Randomized, Controlled Phase 2 Trial of Onvansertib in First-Line RAS-Mutated mCRC at the 2026 ASCO Annual Meeting CRDF GlobeNewswire
Jun-01
Cardiff Oncology to Participate in the Jefferies Global Healthcare Conference CRDF -22.11% GlobeNewswire
May-21
Cardiff Oncology Announces Webcast to Discuss Updated Phase 2 CRDF-004 Data for Onvansertib in First-Line RAS-Mutated mCRC CRDF GlobeNewswire
May-14
Cardiff Oncology Reports First Quarter 2026 Results and Provides Business Update CRDF GlobeNewswire
Apr-28
Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) CRDF GlobeNewswire
Apr-27
Cardiff Oncology to Host Key Opinion Leader Discussion on Onvansertib's Promising Single-Agent Activity CRDF GlobeNewswire
Apr-21
Cardiff Oncology to Present Updated Phase 2 Data of Onvansertib in First-Line RAS-Mutated mCRC in a Rapid Oral Session at ASCO 2026 CRDF -7.30% GlobeNewswire
Apr-17
Cardiff Oncology Presents Preclinical Data on its PLK1 Inhibitor Onvansertib in Combination with a HER2-Targeted ADC at the 2026 AACR Annual Meeting CRDF +6.51% GlobeNewswire
Apr-09
Cardiff Oncology Announces Key Leadership Appointments to Strengthen Executive Team for Next Phase of Growth CRDF +7.05% CRDF -5.39% GlobeNewswire
Mar-20
Cardiff Oncology to Host Key Opinion Leader Discussion Focusing on First-Line RAS-mutated Metastatic Colorectal Cancer CRDF GlobeNewswire
Mar-19
Cardiff Oncology to Present Preclinical Data with Highly Specific PLK1 Inhibitor Onvansertib at the 2026 AACR Annual Meeting CRDF GlobeNewswire
Feb-26
Cardiff Oncology to Participate in Three Upcoming Investor Conferences CRDF GlobeNewswire
Feb-24
Cardiff Oncology Reports Full Year 2025 Results and Provides Business Update CRDF +8.97% CRDF +12.35% GlobeNewswire
Feb-19
Cardiff Oncology to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference CRDF GlobeNewswire
Jan-27
Cardiff Oncology Announces Positive Update from its Randomized Phase 2 Trial of Onvansertib in First-line RAS-mutated mCRC CRDF -31.97% GlobeNewswire
Jan-27
Cardiff Oncology Announces Executive Leadership Changes as it Transitions to Late-Stage Clinical Development CRDF -31.97% GlobeNewswire
Dec-08
Cardiff Oncology Announces Clinical Data from Investigator-Sponsored Trial with Onvansertib in Chronic Myelomonocytic Leukemia at ASH 2025 CRDF +10.90% GlobeNewswire
Dec-08
Cardiff Oncology to Present at Sidoti's Year-End Virtual Investor Conference CRDF +10.90% GlobeNewswire
Nov-24
Cardiff Oncology to Present at the Piper Sandler 37th Annual Healthcare Conference CRDF GlobeNewswire
Nov-06
Cardiff Oncology Reports Third Quarter 2025 Results and Provides Business Update CRDF GlobeNewswire
Nov-04
Cardiff Oncology to Participate in Two Upcoming Investor Conferences CRDF GlobeNewswire
Oct-02
Cardiff Oncology to Participate in Two Upcoming Investor Conferences CRDF GlobeNewswire
Aug-28
Cardiff Oncology to Participate in Three Upcoming Investor Conferences CRDF GlobeNewswire
Jul-29
Cardiff Oncology Announces Positive Data from Ongoing Randomized Phase 2 First-line RAS-mutated mCRC Clinical Trial (CRDF-004) CRDF -11.26% CRDF -24.77% GlobeNewswire
Jul-29
Cardiff Oncology Reports Second Quarter 2025 Results and Provides Business Update CRDF -11.26% CRDF -24.77% GlobeNewswire
Jun-17
Cardiff Oncology Appoints Dr. Roger Sidhu as Chief Medical Officer and Announces Timing for the Next Update from the CRDF-004 Trial in First-Line RAS-mutated mCRC CRDF CRDF -18.38% GlobeNewswire
Jun-02
Cardiff Oncology Announces Positive Data from Investigator-Initiated Trial of Onvansertib in Combination with Paclitaxel in Metastatic Triple-Negative Breast Cancer Presented at ASCO 2025 CRDF GlobeNewswire
May-08
Cardiff Oncology Reports First Quarter 2025 Results and Provides Business Update CRDF +5.62% GlobeNewswire
Affiliate • Advertise • API and Exports • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information
Stock quotes delayed by 1 minute. Futures and options delayed by 15 minutes.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)